Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, will share new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The company will present data demonstrating that its next-generation suppressor tRNAs (sup-tRNAs) restore full‑length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). The company will also present data showing that its novel sup-tRNAs provide durable rescue of full-length titin protein in a mouse model as well as functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM‑TTNtv).
Key takeaways from the announcement include that Tevard’s next‑generation suppressor tRNAs achieve approximately 100% restoration of full‑length dystrophin in DMD models and deliver durable full‑length titin rescue in TTN‑related cardiomyopathy. The company's compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. The presented programs highlight the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner.
This announcement is significant because Duchenne muscular dystrophy and dilated cardiomyopathy caused by TTN truncations are severe genetic disorders with limited treatment options. Nonsense mutations, which introduce premature stop codons, account for a substantial proportion of these diseases. Tevard's suppressor tRNA approach directly addresses the underlying genetic defect by enabling the cellular machinery to read through the premature stop codon and produce full-length, functional protein. If these preclinical results translate to humans, it could represent a paradigm shift in the treatment of nonsense mutation-mediated diseases, offering a one-time therapy that restores native protein expression rather than merely managing symptoms.
The data also underscore the potential of the suppressor tRNA platform beyond muscular dystrophies and cardiomyopathies. Tevard is advancing programs in neurological disorders, and the same technology could be applied to many other genetic conditions caused by nonsense mutations. The compact tRNA design allows for efficient delivery via adeno-associated virus (AAV) vectors, which are already used in approved gene therapies, potentially accelerating the path to clinical development.
For more information, visit www.tevard.com. To view the full announcement, including downloadable images, bios, and more, click here.
